Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Generic Drug Prices in Japan “Not Necessarily High” Compared to Other Countries: Pres. Yoshida of JGA
October 1, 2015
- 2 Firms Mulling Confidentiality Accords to In-License 1st Drug Seed via AMED
September 30, 2015
- Editor’s Pick: Five Healthcare News Headlines for September 14 - September 27
September 29, 2015
- MHLW Gives Greenlight to AbbVie’s Hep C Drug, Other Products
September 29, 2015
- Health Policy Bureau Chief Futagawa Tapped for MHLW’s Top Bureaucratic Post
September 28, 2015
- PMDA Reviewing Daklinza, Sunvepra for Risk of Interstitial Pneumonia
September 28, 2015
- MHLW OKs New Indications for Xarelto, Lamictal, Other Products
September 25, 2015
- Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
- One-Month Lag in Regulatory Filing Accepted for Sakigake Designation
September 24, 2015
- Pharmaceutical Affairs Council Approves Basic Plan for “Humanitarian Trials”
September 24, 2015
- Panel OKs Revised Japanese Pharmacopoeia, 76 Products Newly Included
September 18, 2015
- MHLW to Continue to Suspend HPV Vaccine Recommendation
September 18, 2015
- 51 Products Officially Filed for Sakigake Designation after MHLW Screening
September 18, 2015
- Add Myasthenia Gravis, Myositis to Opdivo Label: MHLW
September 17, 2015
- Toxic Epidermal Necrolysis Added to Clinically Significant ADR List for Vectibix
September 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 24 - September 13
September 15, 2015
- Japan to Help Fight Infectious Diseases in Developing Nations: Basic Policy
September 15, 2015
- Bevacizumab, 2 Other Compounds Designated as Orphan Drugs
September 15, 2015
- Kaketsuken Reports Results of Internal Probe on Improper Blood Product Manufacturing
September 11, 2015
- 1 Million Signatures Collected Opposing Exclusion of Kampo from Reimbursement; “Discussion Closed”: LDP Kampo Supporters
September 11, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…